Coming together at the hinges: Therapeutic prospects of IgG3

• Váldodahkkit: Thach H. Chu (Dahkki), Edward F. Patz (Dahkki), Margaret E. Ackerman (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The human IgG3 subclass is conspicuously absent among the formats for approved monoclonal antibody therapies and Fc fusion protein biologics. Concern about the potential for rapid degradation, reduced plasma half-life, and increased immunogenicity due to marked variation in allotypes has apparently...